Concepedia

Samit Hirawat

SH

Statistics

Publications

27

Citations

9.1K

H-Index

21

Active since

2001

Affiliations

PTC Therapeutics (United States)(Current)

Novartis (Switzerland)

Novartis (United States)

The University of Texas MD Anderson Cancer Center

Institut Gustave Roussy

Samit Hirawat is an author at PTC Therapeutics (United States) specializing in medicine, pharmacology, and oncology.

Top concepts

MedicinePharmacologyOncologyCancer ResearchPharmacotherapyRadiation OncologyPathologyImmunologyBreast CancerCancer Therapy

Publications per year

2001–2020

27

Publications

27

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.4K citations · Full text

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

PTC124 targets genetic disorders caused by nonsense mutations

Ellen Welch, Elisabeth R. Barton, Jin Zhuo et al. · Nature · 2007 · 1.1K citations

Mendelian Disorder, Genetic Disorder, Genetics +4

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · The Lancet Oncology · 2018 · 973 citations

Advanced Breast Cancer, Breast Oncology, Oncology +11

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

Eitan Kerem, Samit Hirawat, S. Armoni et al. · The Lancet · 2008 · 387 citations

Ptc124 Treatment, Molecular Diagnostic Techniques, Mendelian Disorder +4

1–5 of 27